Browse RMM Directory A-Z

${pdf_link}$

Teva UK Patient/Carer Guide to the Safe Use of EFFENTORA®

${pdf_link}$

Teva UK Pharmacist's Guide for Dispensing EFFENTORA®

${pdf_link}$

Teva UK Physicians Guide for Prescribing EFFENTORA®

${pdf_link}$

ELFABRIO®▼ (PEGUNIGALSIDASE ALFA) IMPORTANT INFORMATION: Information for Healthcare Professionals

ELFABRIO®▼ (PEGUNIGALSIDASE ALFA) IMPORTANT INFORMATION on minimising the risk of hypersensitivity reactions and medication errors in home settings Information for Healthcare Professionals

${pdf_link}$

ELFABRIO®▼ (PEGUNIGALSIDASE ALFA) IMPORTANT INFORMATION: Information for Patients, Caregivers and Healthcare Professionals

ELFABRIO®▼ (PEGUNIGALSIDASE ALFA) IMPORTANT INFORMATION on minimising the risk of hypersensitivity reactions and medication errors in home settings Information for Patients, Caregivers and Healthcare Professionals

${pdf_link}$

ELFABRIO®▼ (PEGUNIGALSIDASE ALFA) IMPORTANT INFORMATION: Infusion diary bookletInformation for Patients, Caregivers and Healthcare Professionals

ELFABRIO®▼ (PEGUNIGALSIDASE ALFA) IMPORTANT INFORMATION on minimising the risk of hypersensitivity reactions and medication errors during home infusion Infusion diary booklet

${pdf_link}$

Elidel Educational brochure for HCPs

Important information on the appropriate use of Elidel for HCPs

${pdf_link}$

Eliquis (apixaban) Patient Alert Card

Patients prescribed Eliquis (apixaban) will receive a Patient Alert Card in the medication pack with the package leaflet. Please ensure you have read and understood the information in the card because it contains important safety information including the importance of taking apixaban regularly as instructed by the doctor, the main signs and symptoms of bleeding, and when to seek medical attention. Please carry the Patient Alert Card with you at all times and show it to every healthcare professional including pharmacists. Editorial updates were recently made to the card and the latest version of the card is dated January 2021. If you have lost the copy of the Patient Alert Card that is included in the medication pack, or it is damaged, please contact BMS Medical Information for a replacement copy (telephone: 0800 731 1736; e-mail: [email protected]).

${pdf_link}$

Eliquis (apixaban) Prescriber Guide

This risk minimisation material is for Eliquis for all indications. Please ensure that you are familiar with this material before prescribing Eliquis as it contains important safety information on the potential risk of bleeding during treatment with Eliquis and provides guidance on how to manage that risk. Updates made to the Prescriber Guide in in May 2021 reflect changes to the Summary of Product Characteristics (SPC) for apixaban 2.5 mg and 5 mg tablets on ‘Patients with active cancer’. Other editorial changes were made including updates to the presentation of the Prescriber Guide. If you would like to obtain hard copies of the Eliquis Prescriber Guide and/or Patient Alert Card and/or SPCs, please contact Bristol-Myers Squibb Medical Information (telephone: 0800 731 1736; Email: [email protected]) with your specific request. Risk minimisation materials can only be delivered to UK registered healthcare premises.

${pdf_link}$

CHCs - Checklist for Prescribers

Combined Hormonal Contraceptives - checklist for prescribers

${pdf_link}$

CHCs - Q&A on Important Info for Women

Combined hormonal contraceptives: Q&As about the important information for women.

${pdf_link}$

CHCs - Risk of Blood Clots with CHCs

Important Information for women about risk of blood clots with combined hormonal contraceptives.

${pdf_link}$

Elrexfio (elranatamab) Patient Alert Card

Provides help to patients to understand the risks associated with elranatamab and reminds them to seek immediate medical attention if they experience any of the listed signs and symptoms

${pdf_link}$

Elvanse - Chart for ongoing monitoring of lisdexamfetamine therapy - HCP

${pdf_link}$

Elvanse - Checklist 1: lisdexamfetamine checklist before prescribing - HCP

${pdf_link}$

Elvanse - Checklist 2: checklist for ongoing monitoring of lisdexamfetamine therapy - HCP

${pdf_link}$

Elvanse - potential for non-medical use & diversion of prescription stimulant medications - Pt

${pdf_link}$

Elvanse Adult - Chart for ongoing monitoring of lisdexamfetamine therapy - HCP

${pdf_link}$

Elvanse Adult - Checklist 1: lisdexamfetamine dimesylate checklist before prescribing - HCP

${pdf_link}$

Elvanse Adult - Checklist 2: checklist for ongoing monitoring of lisdexamfetamine dimesylate therapy - HCP

${pdf_link}$

Elvanse Adult - potential for non-medical use & diversion of prescription stimulant medications - Pt

${external_link}$

Emerade Expiry Reminder

Enter your pen expiry dates below and we will remind you to re-order your prescription 30 days before via email. Alternatively you can download a calendar reminder to save in your phone or computer calendar.

${external_link}$

How to use Emerade instruction video

Demonstration video to show you how to use your Emerade autoinjector pen.

${pdf_link}$

Emerres 1.5mg - Patient Advice Leaflet

Patient leaflet explaining about what you may need to do and who you should contact if taking various other medication.

${pdf_link}$

Emerres Una - Patient Advice Leaflet

Includes information for women that are taking other medicines and what you may need to do and who you may need to talk to.

${pdf_link}$

Emerres Una - Patient Questionnaire Checklist

The following list of questions is designed to support you in determining whether Emerres Una is a suitable choice of emergency contraceptive for an individual patient following unprotected sexual intercourse or contraceptive failure.

${pdf_link}$

Emtricitabine/Tenofovir disoproxil Dr. Reddy's 200 mg/245 mg Film-Coated Tablets

Renal and bone effects risk minimisation material: Tenofovir disoproxil for children and adolescents with HIV-1

${pdf_link}$

Checklist for Prescribers v2 Tenofovir PrEP

Initiation of emtricitabine/tenofovir disoproxil for Pre-Exposure Prophylaxis (PrEP) Complete checklist at each visit and file in individuals medical record.

${pdf_link}$

Important Information about Emtricitabine/Tenofovir Disoproxil To Reduce The Risk Of Getting Human Immunodeficiency Virus (HIV) Infection

Information for individuals who have been prescribed emtricitabine/tenofovir disoproxil for Pre-Exposure Prophylaxis (PrEP)

${pdf_link}$

Important Safety Information for prescribers v2 Tenofovir PrEP

Emtricitabine/ tenofovir disoproxil is indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults at high risk. This indication is based on clinical trials in men who have sex with men (MSM) at high risk for HIV-1 infection and on men and women in heterosexual serodiscordant couples.

${pdf_link}$

Reminder Card v2 Tenofovir PrEP

You have been prescribed emtricitabine/ tenofovir disoproxil for PrEP (pre-exposure prophylaxis) to help reduce the risk of getting HIV-1 infection. For this medicine to work effectively it is important that you don’t miss doses. The recommended dose is one emtricitabine/ tenofovir disoproxil tablet each day. Take emtricitabine/ tenofovir disoproxil exactly as your doctor has told you.

${pdf_link}$

Checklist for Prescribers

Initiation of emtricitabine/tenofovir disoproxil for Pre-Exposure Prophylaxis (PrEP)

${pdf_link}$

Important Information about Emticitabine/Tenofovir Disproxil

Information for individuals who have been prescribed emtricitabine/ tenofovir disoproxil for Pre-Exposure Prophylaxis (PrEP)

${pdf_link}$

Important Safety Information for Prescribers

For Prescribers About emtricitabine/ tenofovir disoproxil for a Pre-Exposure Prophylaxis (PrEP) Indication

${pdf_link}$

Reminder Card

EMTRICITABINE/ TENOFOVIR DISOPROXIL FOR PrEP REMINDER CARD

${pdf_link}$

Checklist for Prescribers

${pdf_link}$

Important educational information for patients

Information for individuals who have been prescribed emtricitabine/ tenofovir disoproxil for Pre-Exposure Prophylaxis (PrEP)

${pdf_link}$

Important safety information for prescribers

For Prescribers About emtricitabine/ tenofovir disoproxil for a Pre-Exposure Prophylaxis (PrEP) Indication

${pdf_link}$

Patient reminder card

EMTRICITABINE/ TENOFOVIR DISOPROXIL FOR PrEP REMINDER CARD

${pdf_link}$

CHECKLIST FOR PRESCRIBERS

CHECKLIST FOR PRESCRIBERS Initiation of emtricitabine/tenofovir disoproxil for Pre-Exposure Prophylaxis (PrEP)

${pdf_link}$

EMTRICITABINE/ TENOFOVIR DISOPROXIL FOR PrEP REMINDER CARD

${pdf_link}$

IMPORTANT SAFETY INFORMATION For Prescribers

IMPORTANT SAFETY INFORMATION For Prescribers About emtricitabine/ tenofovir disoproxil for a Pre-Exposure Prophylaxis (PrEP) Indication

${pdf_link}$

Information for individuals

IMPORTANT INFORMATION ABOUT EMTRICITABINE/TENOFOVIR DISOPROXIL TO REDUCE THE RISK OF GETTING HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION Information for individuals who have been prescribed emtricitabine/ tenofovir disoproxil for Pre-Exposure Prophylaxis (PrEP)

${pdf_link}$

Checklist for Prescribers v2 Tenofovir PrEP

${pdf_link}$

Important safety information for individuals using PrEP v2

${pdf_link}$

Important safety information for prescribers v2 Tenofovir PrEP

${pdf_link}$

Reminder card v2 Tenofovir PrEP

${pdf_link}$

Tenofovir HBV indications materials for children and adolescents

${pdf_link}$

Tenofovir HIV indications materials for children and adolescents

${pdf_link}$

Emtricitabine/Tenofovir disoproxil Checklist for Prescribers

Emtricitabine/Tenofovir disoproxil Checklist for Prescribers PrEP

${pdf_link}$

Emtricitabine/Tenofovir Disoproxil Patient Brochure

Patient Brochure for Emtricitabine/Tenofovir disoproxil for PrEP (pre-exposure prophylaxis)

${pdf_link}$

Emtricitabine/Tenofovir Disoproxil Prescriber's Brochure

Important Safety Information for Prescribers About Emtricitabine/Tenofovir Disoproxil for a Pre-exposure Prophylaxis (PrEP) Indication

${pdf_link}$

Patient Reminder Card for Emtricitabine/Tenofovir Disoproxil

Patient Reminder Card for Emtricitabine/Tenofovir disoproxil for PrEP (pre-exposure prophylaxis).

${pdf_link}$

Emtricitabine-Tenofovir Checklist for Prescribers

Emtricitabine-Tenofovir Checklist for Prescribers-v2.0

${pdf_link}$

Emtricitabine-Tenofovir Important educational information for Patients

Important educational information for Patients

${pdf_link}$

Emtricitabine-Tenofovir Important safety information for prescribers

Important safety information for prescribers-v2.0

${pdf_link}$

Emtricitabine-Tenofovir Patient Reminder card

Patient Reminder card-v2.0

${pdf_link}$

Enbrel Patient Alert Card

Enbrel Patient Card

${pdf_link}$

HCP Guide for Prevention of Product Confusion Medication Errors - Enhertu

This HCP guide is a condition of the Marketing Authorisation for Enhertu. It serves to minimise the important potential risk of medication error in addition to the SmPC. HCPs should read it before prescribing and administering Enhertu (trastuzumab deruxtecan). Risk of confusion between Enhertu (trastuzumab deruxtecan) and other trastuzumab-containing products including Kadcyla (trastuzumab emtansine).

${pdf_link}$

HCP Guide: Important Safety Information on ILD/Pneumonitis with treatment of Enhertu

This HCP guide is: - provided for HCPs to read before prescribing and administering Enhertu - an important tool to ensure the early recognition and diagnosis of ILD/pneumonitis, to allow prompt and appropriate treatment and minimise serious outcomes - a reminder to distribute a Patient Card to any patient receiving Enhertu treatment for the first time or if asked for a new copy

${pdf_link}$

Patient Card: Enhertu

- This Patient Card has been provided to you because your doctor has prescribed you Enhertu. - This Patient Card helps you to identify symptoms of lung problems that you may experience with Enhertu. - Read this information before you start receiving Enhertu and before each infusion. - You should keep this card with you at all times and show it to any doctor you consult (for example if your regular doctor is unavailable or if you are travelling).

${pdf_link}$

Important Safety Information for Patients receiving Enspryng®▼ (satralizumab) Patient Card

This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.

${pdf_link}$

Envarsus – prolonged-release tacrolimus tablets

Educational materials for the healthcare professional (doctor or pharmacist) Please read the full Summary of Product Characteristics before prescribing Envarsus

${pdf_link}$

Envarsus Patient Card

Envarsus Prolonged-release tacrolimus tablets Patient Card

${pdf_link}$

Valproate- “White Box” Warning Labels

FOR DISPENSARY USE ONLY Warning Labels with Valproate Pregnancy Pictogram for Pharmacy to use with white box dispensing of these products. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

${pdf_link}$

Valproate DHPC for non-dispensing HCPs

Direct Healthcare Professional Communication for HCPs (non-dispensing) providing background to the updates to the requirements for oral valproate-containing medicines.

${pdf_link}$

Valproate DHPC for Pharmacists

Direct Healthcare Professional Communication for pharmacists providing background to the updates to the requirements for oral valproate-containing medicines.

${pdf_link}$

Valproate Female Annual Risk Acknowledgement Form

THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE Interactive form for use with girls and women of childbearing potential taking this product. It is to be completed with their specialist at least once a year to make sure they know and have understood all the risks related to the use of valproate during pregnancy and the need to avoid becoming pregnant while taking valproate.

${pdf_link}$

Valproate- Healthcare professionals (HCPs) Guide

Educational material for Healthcare Professionals on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

${pdf_link}$

Valproate Male Risk Acknowledgement Form

THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE Interactive form for male patients aged under 55 years to complete with their specialists when starting valproate

${pdf_link}$

Valproate- Patient Card-Contraception and Pregnancy Prevention

Educational material for girls and women of childbearing potential about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

${pdf_link}$

Valproate- Patient Guide

Educational material for patients on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

${pdf_link}$

Valproate- Poster- Dispensary- Pregnancy Prevention Programme

FOR DISPENSARY USE ONLY Dispensary A4 Poster for Pharmacy with key information about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

${pdf_link}$

EpiPen® Carry Card

Carry Card for EpiPen® patients

${external_link}$

EpiPen® Expiry Alert Service

Expiry Alert Service using text or email for EpiPen® patients

${pdf_link}$

EpiPen® Trainer Pen Order Form

Trainer Pen order form

${pdf_link}$

EpiPen® Travel Certificate

Travel Certificate for those carrying EpiPen®

${pdf_link}$

Guide to Using Your EpiPen® & Trainer Pen

Guide to Using Your EpiPen® & Trainer Pen leaflet

${pdf_link}$

HCP Prescription Checklist for EpiPen and EpiPen Jr

Checklist for EpiPen and EpiPen Jr

${pdf_link}$

2021 UK distribution Valproate RMM A4 Pharmacy Poster

FOR DISPENSARY USE ONLY Pharmacy poster with key information about the Pregnancy Prevention Programme.

${pdf_link}$

Patient Card - valproate use in female patients

${pdf_link}$

Patient Guide - valproate

${pdf_link}$

Valproate - Annual Risk Acknowledgement Form Nov 2019

Form for use with girls and women of childbearing potential taking this product. It is to be completed with their specialist at least once a year to make sure they know and have understood all the risks related to the use of valproate during pregnancy and the need to avoid becoming pregnant while taking valproate.

${pdf_link}$

Valproate - Female Annual Risk Acknowledgement Form

${pdf_link}$

Valproate - HCP Guide

${pdf_link}$

Valproate - Male Annual Risk Acknowledgement Form

THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE Interactive form for male patients aged under 55 years to complete with their specialists when starting valproate

${pdf_link}$

Valproate - Poster - Dispensary - Pregnancy Prevention Programme

${pdf_link}$

Valproate - White Box Warning Labels

FOR DISPENSARY USE ONLY Warning Labels with Valproate Pregnancy Pictogram for Pharmacy to use with white box dispensing of these products.

${pdf_link}$

Valproate RMM 2021 Distribution- Patient Booklet

Patient Guide on important safety information associated with Valproate use - educational material

${pdf_link}$

Valproate RMM 2021 UK Distribution- Patient Card

Educational materials for patients on importation safety information card for valproate - Contraception and Pregnancy Prevention

${pdf_link}$

Valproate RMMs 2021 UK Distribution HCP Booklet

Healthcare Professional (HCP) educational material on important safety information associated with Valproate use.

${pdf_link}$

Valproate Warning Stickers UK 2020

FOR DISPENSARY USE ONLY Warning Labels with Valproate Pregnancy Pictogram for Pharmacy to use with white box dispensing of these products.

${pdf_link}$

Valproate - “White Box” Warning Labels

FOR DISPENSARY USE ONLY Warning Labels with Valproate Pregnancy Pictogram for Pharmacy to use with white box dispensing of these products.. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]

${pdf_link}$

Valproate - Healthcare professionals (HCPs) Guide - Pregnancy Prevention Programme

Educational material for Healthcare Professionals on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]

${pdf_link}$

Valproate - Patient Card - Contraception and Pregnancy Prevention

Educational material for girls and women of childbearing potential about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]

${pdf_link}$

Valproate - Patient Guide

Educational material for patients on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]

${pdf_link}$

Valproate - Poster - Dispensary - Pregnancy Prevention Programme

FOR DISPENSARY USE ONLY Dispensary A4 Poster for Pharmacy with key information about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]

${pdf_link}$

Valproate Female Annual Risk Acknowledgement Form

THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE Interactive form for use with girls and women of childbearing potential taking this product. It is to be completed with their specialist at least once a year to make sure they know and have understood all the risks related to the use of valproate during pregnancy and the need to avoid becoming pregnant while taking valproate.

${pdf_link}$

Valproate Male Annual Risk Acknowledgement Form

THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE Interactive form for male patients aged under 55 years to complete with their specialists when starting valproate

${pdf_link}$

Epysqli Certificate of Vaccination

This form is to be used by healthcare professionals to confirm that the patient has received or will receive meningococcal vaccination and/or antibiotic prophylaxis in accordance with the meningococcal vaccination requirements set out in the certificate.

${pdf_link}$

EPYSQLI Patient Safety Card

Important Safety Information for Patients Receiving EPYSQLI. Show this card to any doctor involved in your care.

${pdf_link}$

EPYSQLI Patient/Parent Information

This guide is for adult patients and parents/legal guardians of a child who has been prescribed eculizumab. The guide provides you with important safety information that you must be aware of.

${pdf_link}$

EPYSQLI Physician's Guide

The aim of this brochure is to educate and/or remind healthcare professionals about the selected prevention measures, detection, careful monitoring and/or proper management of selected safety concerns associated with eculizumab.

${pdf_link}$

Equasym - ADHD physicians guide to prescribing - July2021

${pdf_link}$

Equasym - Chart for ongoing monitoring during methylphenidate treatment - HCP - July2021

${pdf_link}$

Equasym - Checklist 1: checklist before prescribing - HCP - July2021

${pdf_link}$

Equasym - Checklist 2: checklist for monitoring of ongoing therapy - HCP - July2021

${pdf_link}$

Erelzi (Etanercept) Patient Card

The Patient card contains information on the following for patients treated with Erelzi: - Use in children and adolescents - Opportunistic infections and tuberculosis (TB) - Congestive Heart Failure (CHF).

${pdf_link}$

Erivedge (vismodegib) HCP Reminder Card

This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.

${pdf_link}$

Erivedge (vismodegib) Pharmacist Dispensing Checklist

This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.

${pdf_link}$

Erivedge (vismodegib) Pharmacists Confirmation of Role Form

This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.

${pdf_link}$

Erivedge (vismodegib) Pregnancy Prevention Programme Patient Booklet

This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.

${pdf_link}$

Erivedge (vismodegib) Pregnancy Prevention Programme Patient Counselling Guidelines

This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.

${pdf_link}$

Erivedge (vismodegib) Prescriber Confirmation of Role Form

This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.

${pdf_link}$

Esbriet (pirfenidone) Safety Checklist for Prescribing Physicians

This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan

${pdf_link}$

Pathologist's Guide - Esmya

Guide for pathologists dealing with gynaecological tissue which may have been exposed to Esmya (Ulipristal acetate) - revised Feb 2021.

${pdf_link}$

Patient Card - Esmya

This patient card will be present in the Esmya pack and is intended for the patient.

${pdf_link}$

Physician's Guide to Prescribing - Esmya

Educational material for prescribers - revised Feb 2021

${pdf_link}$

Health Professionals’ Guide

Health Professionals’ Guide containing important information about Espranor

${pdf_link}$

Patients’ Guide - Information for HCP to give to patients prescribed Espranor

This is an Educational Material, for health professionals to give to patients prescribed Espranor

${pdf_link}$

Evenity Patient Alert Card

This Patient alert card contains important safety information. The patient and, if appropriate their caregiver should be educated about treatment risks and provided with a Patient Alert Card.

${pdf_link}$

Evenity Prescriber Guide

This guide is developed to increase awareness and educate prescribers about the important identified risks of serious cardiovascular events of MI and stroke and of hypocalcaemia and important potential risk of ONJ, and the appropriate prevention, early diagnosis and adequate management of these events.

${pdf_link}$

Annex 2 CHC Prescriber Checklist

Please use this checklist in conjunction with the Summary of Product Characteristics during combined hormonal contraceptive (CHC) consultations.

${pdf_link}$

Annex 3 CHC User Card

Important Information for Women - Summary of risk of blood clots with combined hormonal contraception.

${pdf_link}$

Annex 4 Important Information for Women

Leaflet with information on combined oral contraception to be given to the patient by the physician.

${pdf_link}$

Rivastigmine patch (Exelon/Prometax) - Instructions for use and patient diary - for patients

Instructions for use and a patient diary including medication record sheets for patients that have been prescribed Exelon Patch or Prometax Patch (rivastigmine transdermal system) to ensure the correct use of the patch.

${pdf_link}$

Exjade (deferasirox): Important information for patients about your treatment and possible side effects.

Please keep this document safe for future reference. This booklet is only intended for patients that have been prescribed deferasirox. It contains important information, including how to take deferasirox the right way, why monitoring your treatment is important, and which medicines you can take while on deferasirox.

${pdf_link}$

Risk Minimisation Materials

Effentora

Teva Pharma B.V.

Elfabrio

Chiesi Limited

Elidel

Mylan

Eliquis

Bristol-Myers Squibb-Pfizer

ELOINE

Bayer plc

Elrexfio

Pfizer Limited

Elvanse

Takeda UK Ltd

Emerade

Bausch & Lomb U.K Limited

Emerres

Morningside Healthcare Ltd

Emtricitabine+Tenofovir

Dr. Reddy's Laboratories (UK) Ltd

Lupin Healthcare (UK) Ltd

Tillomed Laboratories Ltd

Amarox Limited

ADVANZ Pharma

Mylan

Aurobindo Pharma - Milpharm Ltd.

Enbrel

Pfizer Limited

Enhertu

Daiichi Sankyo UK Limited

Enspryng

Roche Products Limited

Envarsus

Chiesi Limited

Epilim

SANOFI

EpiPen

Mylan

Episenta

Desitin Pharma Ltd

Epival

G.L Pharma UK Limited

Epysqli

Samsung Bioepis UK Limited

Equasym

Takeda UK Ltd